Positive Phase I results for Allergy’s Acarovac
Good news for patients with house dust mite-induced allergic rhinoconjunctivitis.
Read More
Tag: rhinoconjunctivitis
Circassia’s cat allergy drug fails to hit trial targets
Shares in UK biotech Circassia have plummeted after its flagship experimental cat allergy drug failed to hit targets in a Phase III trial.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
